Related Experiment Videos
Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection
L P Seung1, D A Rowley, P Dubey
1Department of Pathology, University of Chicago, IL 60637, USA.
Abstract:
During tumor progression, variants may arise that grow more vigorously. The fate of such variants depends upon the balance between aggressiveness of the variant and the strength of the host immunity. Although enhancing host immunity to cancer is a logical objective, eliminating host factors necessary for aggressive growth of the variant should also be considered. The present study illustrates this concept in the model of a spontaneously occurring, progressively growing variant of an ultraviolet light-induced tumor. The variant produces chemotactic factors that attract host leukocytes and is stimulated in vitro by defined growth factors that can be produced or induced by leukocytes. This study also shows that CD8+ T-cell immunity reduces the rate of tumor growth; however, the variant continues to grow and kills the host. Treatment with a monoclonal anti-granulocyte antibody that counteracts the infiltration of the tumor cell inoculum by non-T-cell leukocytes did not interfere with the CD8+ T-cell-mediated immune response but resulted in rejection of the tumor challenge, indicating a synergy between CD8+ T-cell-mediated immunity and the inhibition of paracrine stimulation.
Insights
Aggressive tumor variants can be controlled by enhancing host immunity or by blocking host factors that promote their growth. Combining CD8+ T-cell immunity with anti-granulocyte treatment effectively rejected a progressively growing tumor variant.
Area of Science:
- Immunology
- Oncology
- Cancer Biology
Background:
- Tumor progression involves the emergence of aggressive variants.
- Host immunity and tumor aggressiveness dictate variant fate.
- Enhancing immunity or reducing tumor growth factors are potential strategies.
Purpose of the Study:
- To investigate the interplay between tumor variant aggressiveness and host immunity.
- To explore therapeutic strategies targeting both tumor growth factors and host immunity.
Main Methods:
- Utilized a model of ultraviolet light-induced tumor variant.
- Assessed the impact of CD8+ T-cell immunity on tumor growth.
- Investigated the effect of anti-granulocyte antibody treatment on tumor rejection.
Main Results:
- CD8+ T-cell immunity reduced tumor growth rate but did not prevent host death.
- Monoclonal anti-granulocyte antibody treatment led to tumor rejection.
- Combined CD8+ T-cell immunity and anti-granulocyte treatment showed synergistic effects.
Conclusions:
- Blocking host factors like granulocyte infiltration synergizes with T-cell immunity for tumor rejection.
- Targeting both tumor-promoting host factors and adaptive immunity offers a promising therapeutic approach.